Zogenix Inc logo

ZGNX - Zogenix Inc Share Price

$46.86 1.3  2.8%

Last Trade - 06/12/19

Sector
Healthcare
Size
Mid Cap
Market Cap £1.53bn
Enterprise Value £1.34bn
Revenue £1.29m
Position in Universe 1849th / 6416
Bullish
Bearish
Unlock ZGNX Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ZGNX Revenue Unlock ZGNX Revenue

Net Income

ZGNX Net Income Unlock ZGNX Revenue

Normalised EPS

ZGNX Normalised EPS Unlock ZGNX Revenue

PE Ratio Range

ZGNX PE Ratio Range Unlock ZGNX Revenue

Dividend Yield Range

ZGNX Dividend Yield Range Unlock ZGNX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ZGNX EPS Forecasts Unlock ZGNX Revenue
Profile Summary

Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. ZX008 has received orphan drug designation in the United States and European Union (EU), for the treatment of Dravet syndrome. The Company has an additional product candidate, Relday (risperidone once-monthly long-acting injectable) for the treatment of schizophrenia. Relday is a long-acting injectable formulation of risperidone. Risperidone is used to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. It has completed the Phase I program for Relday.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated May 11, 2006
Public Since November 23, 2010
No. of Shareholders: 10
No. of Employees: 136
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 44,254,761
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ZGNX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ZGNX
Upcoming Events for ZGNX
Similar to ZGNX
© Stockopedia 2019, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.